11 research outputs found

    Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex

    Get PDF
    Ciclopirox (CPX) is an FDA-approved topical antifungal agent that has demonstrated preclinical anticancer activity in a number of solid and hematologic malignancies. Its clinical utility as an oral anticancer agent, however, is limited by poor oral bioavailability and gastrointestinal toxicity. Fosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following parenteral administration. We characterized the activity of CPX-POM and its major metabolites in in vitro and in vivo preclinical models of high-grade urothelial cancer. CPX inhibited cell proliferation, clonogenicity and spheroid formation, and increased cell cycle arrest at S and G0/G1 phases. Mechanistically, CPX suppressed activation of Notch signaling. Molecular modeling and cellular thermal shift assays demonstrated CPX binding to γ-secretase complex proteins Presenilin 1 and Nicastrin, which are essential for Notch activation. To establish in vivo preclinical proof of principle, we tested fosciclopirox in the validated N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) mouse bladder cancer model. Once-daily intraperitoneal administration of CPX-POM for four weeks at doses of 235 mg/kg and 470 mg/kg significantly decreased bladder weight, a surrogate for tumor volume, and resulted in a migration to lower stage tumors in CPX-POM treated animals. This was coupled with a reduction in the proliferation index. Additionally, there was a reduction in Presenilin 1 and Hes-1 expression in the bladder tissues of CPX-POM treated animals. Following the completion of the first-in-human Phase 1 trial (NCT03348514), the pharmacologic activity of fosciclopirox is currently being characterized in a Phase 1 expansion cohort study of muscle-invasive bladder cancer patients scheduled for cystectomy (NCT04608045) as well as a Phase 2 trial of newly diagnosed and recurrent urothelial cancer patients scheduled for transurethral resection of bladder tumors (NCT04525131)

    IQGAP1 is a novel CXCR2-interacting protein and essential component of the "chemosynapse".

    Get PDF
    Chemotaxis is essential for a number of physiological processes including leukocyte recruitment. Chemokines initiate intracellular signaling pathways necessary for chemotaxis through binding seven transmembrane G protein-couple receptors. Little is known about the proteins that interact with the intracellular domains of chemokine receptors to initiate cellular signaling upon ligand binding. CXCR2 is a major chemokine receptor expressed on several cell types, including endothelial cells and neutrophils. We hypothesize that multiple proteins interact with the intracellular domains of CXCR2 upon ligand stimulation and these interactions comprise a "chemosynapse", and play important roles in transducing CXCR2 mediated signaling processes.In an effort to define the complex of proteins that assemble upon CXCR2 activation to relay signals from activated chemokine receptors, a proteomics approach was employed to identify proteins that co-associate with CXCR2 with or without ligand stimulation. The components of the CXCR2 "chemosynapse" are involved in processes ranging from intracellular trafficking to cytoskeletal modification. IQ motif containing GTPase activating protein 1 (IQGAP1) was among the novel proteins identified to interact directly with CXCR2. Herein, we demonstrate that CXCR2 co-localizes with IQGAP1 at the leading edge of polarized human neutrophils and CXCR2 expressing differentiated HL-60 cells. Moreover, amino acids 1-160 of IQGAP1 directly interact with the carboxyl-terminal domain of CXCR2 and stimulation with CXCL8 enhances IQGAP1 association with Cdc42.Our studies indicate that IQGAP1 is a novel essential component of the CXCR2 "chemosynapse"

    VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis

    No full text
    Chemotaxis regulates the recruitment of leukocytes, which is integral for a number of biological processes and is mediated through the interaction of chemokines with seven transmembrane G-protein-coupled receptors. Several studies have indicated that chemotactic signaling pathways might be activated via G-protein-independent mechanisms, perhaps through novel receptor-interacting proteins. CXCR2 is a major chemokine receptor expressed on neutrophils. We used a proteomics approach to identify unique ligand-dependent CXCR2-interacting proteins in differentiated neutrophil-like HL-60 cells. Using this approach, vasodilator-stimulated phosphoprotein (VASP) was identified as a CXCR2-interacting protein. The interaction between CXCR2 and VASP is direct and enhanced by CXCL8 stimulation, which triggers VASP phosphorylation via PKA- and PKCδ-mediated pathways. The interaction between CXCR2 and VASP requires free F-actin barbed ends to recruit VASP to the leading edge. Finally, knockdown of VASP in HL-60 cells results in severely impaired CXCR2-mediated chemotaxis and polarization. These data provide the first demonstration that direct interaction of VASP with CXCR2 is essential for proper CXCR2 function and demonstrate a crucial role for VASP in mediating chemotaxis in leukocytes

    Data for Temporal and spatial variability of ammonia in urban and agricultural regions of northern Colorado, United States

    No full text
    Concentrated agricultural activities and animal feeding operations in the northeastern plains of Colorado represent an important source of atmospheric ammonia (NH3) that contributes to regional fine particle formation and to nitrogen deposition to sensitive ecosystems in Rocky Mountain National Park (RMNP) located ~ 80 km to the west. In order to better understand temporal and spatial differences in NH3 concentrations in this source region, weekly concentrations of NH3 were measured at 14 locations during the summers of 2010 to 2015 using Radiello passive NH3 samplers. Weekly (biweekly in 2015) average NH3 concentrations ranged from 2.66 μg/m3 to 42.7 μg/m3 with the highest concentrations near large concentrated animal feeding operations (CAFOs). The annual summertime mean NH3 concentrations were stable in this region from 2010 to 2015, providing a baseline against which concentration changes associated with future changes in regional NH3 emissions can be assessed. Vertical profiles of NH3 were also measured on the 300 m Boulder Atmospheric Observatory (BAO) tower throughout 2012. The highest NH3 concentration along the vertical profile was always observed at the 10 m height (annual average concentration of 4.63 μg/m3), decreasing toward the surface (4.35 μg/m3) and toward higher altitudes (1.93 μg/m3). Seasonal changes in the steepness of the vertical concentration gradient were observed, with the sharpest gradients in cooler seasons when thermal inversions restricted vertical mixing of surface-based emissions. The NH3 spatial distributions measured using the passive samplers are compared with NH3 columns retrieved by the Infrared Atmospheric Sounding Interferometer (IASI) satellite and concentrations simulated by the Comprehensive Air quality Model with extensions (CAMx), providing insight into the regional performance of each. The satellite comparison adds to a growing body of evidence that IASI column retrievals of NH3 provide very useful insight into regional variability in atmospheric NH3, in this case even in a region with strong local sources and sharp spatial gradients. The CAMx comparison indicates that the model does a reasonable job simulating NH3 concentrations near sources but tends to underpredict concentrations at locations farther downwind. Excess NH3 deposition by the model is hypothesized as a possible explanation for this trend
    corecore